Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer

Journal of Surgical Oncology

Volumn 101, Issue 2, 2010, Pages 149-155

  Kim, Jin Hwi ^a   Lee, Joon Mo ^a   Ryu, Ki Sung ^a   Lee, Yong Seok ^b   Park, Yong Gyu ^c   Hur, Soo Young ^a   Lee, Keun Ho ^a   Lee, Sung Ha ^a   Kim, Seung Jo ^d  

^a The Catholic University of Korea   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d CHA University   (South Korea)

Author keywords

Consolidation; HIPEC; Ovarian carcinoma; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; RINGER LACTATE SOLUTION; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; EPITHELIAL OVARIAN CANCER; FEASIBILITY STUDY; FEMALE; HUMAN; HYPERTHERMIA; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; LAPAROTOMY; MALE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERITONEUM CELL; PRIORITY JOURNAL; SAFETY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 76549105166     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21448     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Kyrgiou M, Salanti G, Pavlidis N, et al.: Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments. J Natl Cancer Inst 2006;98:1655-1663.
3. Diaz-Montes TP, Bristow RE: Secondary cytoreduction for patients with recurrent ovarian cancer. Curr Oncol Rep 2005;7: 451-458.
4. Gadducci A, Cosio S, Conte PF, et al.: Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. Crit Rev Oncol Hematol 2005;55:153-166.
5. Alberts DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
6. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34-43.
7. Markman M, Bundy BN, Alberts DS, et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007.
8. Walker JL, Armstrong DK, Huang HQ, et al.: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2006;100:27-32.
9. Witkamp AJ, de Bree E, Van Goethem R, et al.: Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001;27:365-374.
10. Sticca RP, Dach BW: Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003;12:689-701.
11. Sugarbaker PH, Chang D: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727-731.
12. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284-3292.
13. Piso P, Dahlke MH, Loss M, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2004;2:21.
14. Cotte E, Glehen O, Mohamed F, et al.: Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: Prospective study of 81 patients. World J Surg 2007;31:1813-1820.
15. Bae JH, Lee JM, Ryu KS, et al.: Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 2007; 106:193-200.
16. Di Giorgio A, Naticchioni E, Biacchi D, et al.: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008;113: 315-325.
17. Helm CW, Bristow RE, Kusamura S, et al.: Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 2008;98:283-290.
18. National Cancer Institute, Common Toxicity Creiteria (CTC) (veration 2). In, April 30, 1999.
19. Rubin SC, Randall TC, Armstrong KA, et al.: Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21-24.
20. Markman M, Liu PY, Wilczynski S, et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465.
21. Thigpen J: Current controversies in ovarian cancer: Maintenance chemotherapy as standard care. In: Perry MC (editor): "American society of clinical oncology, 40th annual meeting." New Orleans, LA, 2004;281-284.
22. Conte PF: Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT). J Clin Oncol 2007;25:5505.
23. Zanon C, Clara R, Chiappino I, et al.: Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer.World J Surg 2004;28:1040-1045.
24. Hager ED, Dziambor H, Hohmann D, et al.: Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001;11:57-63.
25. Ryu KS, Kim JH, Ko HS, et al.: Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004;94:325-332.
26. Raspagliesi F, Kusamura S, Campos Torres JC, et al.: Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006;32:671-675.
27. Oleson J: Hyperthermia. Philadelphia: JB Lippincott Company; 1989.
28. Yoshida Y, Sasaki H, Kurokawa T, et al.: Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up. Oncol Rep 2005;13:121-125.
29. Gori J, Castano R, Toziano M, et al.: Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005; 15:233-239.
30. Markman M, Rowinsky E, Hakes T, et al.: Phase I trial of intraperitoneal taxol: A Gynecoloic Oncology Group study. J Clin Oncol 1992;10:1485-1491.
31. de Bree E, Rosing H, Filis D, et al.: Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: A clinical and pharmacokinetic study. Ann Surg Oncol 2008;15:1183-1192.